Katyna Borroto-Esoda

Summary

Affiliation: Gilead Sciences
Country: USA

Publications

  1. ncbi Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails
    Jennifer P Mewshaw
    Triangle Pharmaceuticals, Durham, North Carolina, USA
    J Acquir Immune Defic Syndr 29:11-20. 2002
  2. ncbi Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz
    Katyna Borroto-Esoda
    Gilead Sciences, Inc, 4611 University Drive, Durham, North Carolina 27707, USA
    AIDS Res Hum Retroviruses 23:988-95. 2007
  3. doi The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, 4 University Place, 4611 University Drive, Durham, NC 27707, USA
    J Acquir Immune Defic Syndr 48:428-36. 2008
  4. ncbi A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine
    Katyna Borroto-Esoda
    Gilead Sciences, Inc, Foster City, CA, USA
    Antivir Chem Chemother 18:297-300. 2007
  5. ncbi In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine
    Katyna Borroto-Esoda
    Department of Clinical Virology, Gilead Sciences, Inc, Foster City, CA, USA
    Antivir Ther 11:377-84. 2006
  6. pmc In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1
    Katyna Borroto-Esoda
    Gilead Sciences Inc, 4611 University Dr, Durham, NC 27707, USA
    Antimicrob Agents Chemother 48:4387-94. 2004
  7. ncbi Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, Durham, NC, USA
    J Acquir Immune Defic Syndr 46:174-80. 2007
  8. ncbi Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients
    Joshua M Waters
    Gilead Sciences, Inc, Durham, NC, USA
    Antivir Ther 14:231-9. 2009
  9. ncbi Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine
    Joy Y Feng
    Gilead Science, 4 University Place, 4611 University Drive, Durham, NC 27707, USA
    Antiviral Res 66:153-8. 2005
  10. doi Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy
    Derrick D Goodman
    Gilead Sciences Inc, Durham, North Carolina, USA
    AIDS 25:325-33. 2011

Collaborators

Detail Information

Publications28

  1. ncbi Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails
    Jennifer P Mewshaw
    Triangle Pharmaceuticals, Durham, North Carolina, USA
    J Acquir Immune Defic Syndr 29:11-20. 2002
    ..We also examined site-directed mutants containing only L74V or K65R, the characteristic resistance mutations for DXG. The L74V mutant remained susceptible to inhibition by DXG, and the K65R mutant demonstrated moderate resistance to DXG...
  2. ncbi Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz
    Katyna Borroto-Esoda
    Gilead Sciences, Inc, 4611 University Drive, Durham, North Carolina 27707, USA
    AIDS Res Hum Retroviruses 23:988-95. 2007
    ....
  3. doi The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, 4 University Place, 4611 University Drive, Durham, NC 27707, USA
    J Acquir Immune Defic Syndr 48:428-36. 2008
    ..In clinical isolates, K65R is frequently accompanied by the A62V and S68G reverse transcriptase mutations...
  4. ncbi A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine
    Katyna Borroto-Esoda
    Gilead Sciences, Inc, Foster City, CA, USA
    Antivir Chem Chemother 18:297-300. 2007
    ..FTC and 3TC demonstrate nearly identical phenotypic resistance profiles and have the same biological cutoff in this panel of NRTI-R and WT clinical HIV-1 isolates...
  5. ncbi In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine
    Katyna Borroto-Esoda
    Department of Clinical Virology, Gilead Sciences, Inc, Foster City, CA, USA
    Antivir Ther 11:377-84. 2006
    ..We evaluated this combination for anti-HIV activity and intracellular metabolic interactions in vitro...
  6. pmc In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1
    Katyna Borroto-Esoda
    Gilead Sciences Inc, 4611 University Dr, Durham, NC 27707, USA
    Antimicrob Agents Chemother 48:4387-94. 2004
    ..These studies suggest a potential role for the use of IMPDH inhibitors in combination therapy with amdoxovir in the treatment of HIV...
  7. ncbi Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, Durham, NC, USA
    J Acquir Immune Defic Syndr 46:174-80. 2007
    ..Prior abacavir (ABC) or didanosine (ddI) therapy can result in the L74V/I or K65R mutation in HIV-1 reverse transcriptase. Preexisting K65R may have an impact on the treatment response to tenofovir disoproxil fumarate (TDF)...
  8. ncbi Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients
    Joshua M Waters
    Gilead Sciences, Inc, Durham, NC, USA
    Antivir Ther 14:231-9. 2009
    ..Antiretroviral therapy that targets HIV type-1 (HIV-1) reverse transcriptase (RT) can be linked to mutations in the thumb-connection (amino acids [AA] 241-426) and RNase H (AA 427-560) domains, which could affect drug resistance...
  9. ncbi Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine
    Joy Y Feng
    Gilead Science, 4 University Place, 4611 University Drive, Durham, NC 27707, USA
    Antiviral Res 66:153-8. 2005
    ..9-fold), while the binding affinity of A62V HIV-1 RT for DXG-TP was decreased 14-fold. At the enzyme level, the addition of the A62V mutation to V75I/F77L/F116Y/Q151M moderately (3.4-fold) reversed the resistance to DXG-TP...
  10. doi Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy
    Derrick D Goodman
    Gilead Sciences Inc, Durham, North Carolina, USA
    AIDS 25:325-33. 2011
    ..Here, we analyzed whether the presence of low levels of K103N at baseline correlated with virologic failure...
  11. ncbi Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine
    Joy Y Feng
    Gilead Sciences, Inc, Durham, North Carolina, USA
    Nucleosides Nucleotides Nucleic Acids 25:89-107. 2006
    ..The Q151M mutation remained sensitive to both FTC and 3TC in both cell culture and enzymatic assays. At a molecular level, FTC-TP was incorporated at least as efficiently as 3TC-TP for all of the HIV-1 RT and primer/templates tested...
  12. ncbi Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir
    Maria Curtis
    Gilead Sciences, 4 University Place, Durham, NC 27707, USA
    J Infect Dis 196:1483-6. 2007
    ..Phenotypic evaluation of clinical isolates and of a laboratory strain with the rtI233V mutation demonstrated their full susceptibility to adefovir in vitro, and HBV with the rtI233V mutation developed in none of the patients...
  13. doi The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations
    Yuao Zhu
    Gilead Sciences, Inc, Foster City, CA, USA
    Antivir Chem Chemother 22:13-22. 2011
    ..rtA194T was reportedly associated with tenofovir resistance. We investigated these findings in genotype D HBV, where both PC and BCP naturally occur in vivo...
  14. pmc The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study
    Joy Y Feng
    Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, California 94404, USA
    Retrovirology 6:44. 2009
    ....
  15. doi No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus
    Andrea Snow-Lampart
    Gilead Sciences, Incorporated, Durham, NC, USA
    Hepatology 53:763-73. 2011
    ..Persistent viremia (≥400 copies/mL) through week 144 was rare (5/641, 0.8%) and was not associated with virological resistance to TDF by population or clonal analyses...
  16. pmc In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations
    Yuao Zhu
    Gilead Sciences, Inc, 4611 University Drive, Durham, NC 27707, USA
    J Clin Microbiol 45:3335-41. 2007
    ....
  17. doi HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays
    Yuao Zhu
    Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA 94404, United States
    J Virol Methods 173:340-6. 2011
    ..In conclusion, a phenotyping assay for HBV RT gene was developed, allowing evaluation of patient-derived HBV RT from genotypes A-H, and confirmed the drug resistance phenotype in samples containing LAM-R or ADV-R mutations...
  18. ncbi Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues
    Yuao Zhu
    Gilead Sciences, Inc, Durham, NC, USA
    Antivir Chem Chemother 19:165-76. 2009
    ..We therefore evaluated the in vitro anti-HBV activity of tenofovir (TFV), the active parent drug of TDF, combined with FTC, 3TC, ETV, LdT and adefovir (AFV)...
  19. ncbi Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials
    Katyna Borroto-Esoda
    Department of Clinical Virology, Gilead Sciences, Inc, 4 University Place, 4611 University Dr, Durham, NC 27707, USA
    J Hepatol 47:492-8. 2007
    ..Recent reports have proposed other ADV resistance (ADV-R) mutations. The aims of this study were to confirm the role of rtA181V and rtN236T in clinical resistance to ADV and to screen for other potential ADV-R mutations...
  20. doi Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz
    Damian J McColl
    Gilead Sciences, Inc, Foster City, CA, USA
    HIV Clin Trials 12:61-70. 2011
    ....
  21. pmc MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples
    Evguenia S Svarovskaia
    Gilead Sciences, Inc, 4 University Place, 4611 University Drive, Durham, NC 27707, USA
    J Clin Microbiol 44:4237-41. 2006
    ..Fifty-three treatment-naïve and 20 treatment-experienced specimens were successfully genotyped with the new method. Results were in agreement with population sequencing and the labor-intensive single-genome sequencing method...
  22. ncbi Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 5'-phosphates by mammalian phosphotransferases
    Joy Y Feng
    Gilead Sciences, 4 University Place, 4611 University Drive, Durham, NC 27707, USA
    Biochem Pharmacol 68:1879-88. 2004
    ..5 nM) of DXG-TP was detected as the primary metabolite. Our study demonstrated that 5'-nucleotidase, GMP kinase, creatine kinase, and NDP kinase could be responsible for the activation of DXG in vivo...
  23. doi Therapy of chronic hepatitis B: trends and developments
    William E Delaney
    Gilead Sciences, 333 Lakeside Dr Foster City, CA 94404, USA
    Curr Opin Pharmacol 8:532-40. 2008
    ..The challenge is how to best use these drugs long-term to minimize antiviral resistance and maintain maximal antiviral suppression, which is anticipated to make the greatest impact on limiting advanced complications of CHB...
  24. ncbi Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial
    Michael S Saag
    University of Alabama Research Clinic, Birmingham, USA
    JAMA 292:180-9. 2004
    ..Emtricitabine is a new, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV)...
  25. ncbi Molecular mechanism of DApd/DXG against zidovudine- and lamivudine- drug resistant mutants: a molecular modelling approach
    Youhoon Chong
    Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, The University of Georgia, Athens, USA
    Antivir Chem Chemother 13:115-28. 2002
    ..The enzyme-inhibitor complexes with good binding affinity showed tight binding modes by closing the gap between the two domains, whereas weak inhibitors gave open and loose complexes...
  26. ncbi Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results
    Eugene Schiff
    Center for Liver Diseases, University of Miami, Miami, FL 33136, USA
    Liver Transpl 13:349-60. 2007
    ..In conclusion, adefovir dipivoxil is effective and safe in wait-listed or posttransplantation CHB patients with lamivudine-resistant HBV and prevents graft reinfection with or without HBIg...
  27. doi Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
    Patrick Marcellin
    Hopital Beaujon, Paris, France
    Hepatology 48:750-8. 2008
    ..Adefovir resistance mutations A181V or N236T developed in 13 LTSES patients; the first observation was at study week 195. There were no serious adverse events related to ADV...
  28. ncbi Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Gastroenterology 131:1743-51. 2006
    ..We investigated the efficacy, safety, and resistance profile of adefovir dipivoxil treatment for up to 240 weeks...